Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company, identifies and develops therapies for the treatment of cancer. More Details
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has Senhwa Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6492 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 6492's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of TW stocks.
7 Day Return
1 Year Return
Return vs Industry: 6492 exceeded the TW Biotechs industry which returned 22.9% over the past year.
Return vs Market: 6492 exceeded the TW Market which returned 31.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Senhwa Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StDoes This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?
2 months ago | Simply Wall StSenhwa Biosciences, Inc. (GTSM:6492) Is Expected To Breakeven In The Near Future
5 months ago | Simply Wall StWe're Not Very Worried About Senhwa Biosciences' (GTSM:6492) Cash Burn Rate
Is Senhwa Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 6492 (NT$190.5) is trading above our estimate of fair value (NT$140.49)
Significantly Below Fair Value: 6492 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 6492 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 6492 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6492's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6492 is overvalued based on its PB Ratio (7.1x) compared to the TW Biotechs industry average (4.8x).
How is Senhwa Biosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6492 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Earnings vs Market: 6492 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 6492's is expected to become profitable in the next 3 years.
Revenue vs Market: 6492's revenue (110% per year) is forecast to grow faster than the TW market (11.2% per year).
High Growth Revenue: 6492's revenue (110% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6492's Return on Equity is forecast to be high in 3 years time (30.9%)
How has Senhwa Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6492 is currently unprofitable.
Growing Profit Margin: 6492 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6492 is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare 6492's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6492 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 6492 has a negative Return on Equity (-14.63%), as it is currently unprofitable.
How is Senhwa Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: 6492's short term assets (NT$2.5B) exceed its short term liabilities (NT$76.5M).
Long Term Liabilities: 6492's short term assets (NT$2.5B) exceed its long term liabilities (NT$3.7M).
Debt to Equity History and Analysis
Debt Level: 6492's debt to equity ratio (0.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 6492's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6492 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6492 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Senhwa Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6492's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6492's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6492's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6492's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6492's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Tai-Sen Soong, Ph.D. is a Co-Founder of Medtech Tronics, Inc. Dr. Soong serves as the President and Vice Chairman at CDIB BioScience Venture Management. Dr. Soong serves as Chief Executive Officer at S...
CEO Compensation Analysis
Compensation vs Market: Tai-Sen's total compensation ($USD525.38K) is about average for companies of similar size in the TW market ($USD442.53K).
Compensation vs Earnings: Insufficient data to compare Tai-Sen's compensation with company performance.
|CEO, President & Director||no data||NT$14.72m||no data|
|Chairman||no data||no data||no data|
|Supervisor||5.83yrs||no data||no data|
|Director||8.17yrs||no data||no data|
|Supervisor||4.58yrs||no data||no data|
|Independent Director||5.83yrs||NT$60.00k||no data|
|Director||3.58yrs||no data||no data|
|Independent Director||5.83yrs||NT$80.00k||no data|
|Supervisor||3.58yrs||no data||no data|
Experienced Board: 6492's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.3%.
Senhwa Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Senhwa Biosciences, Inc.
- Ticker: 6492
- Exchange: GTSM
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$16.131b
- Shares outstanding: 89.62m
- Website: https://www.senhwabio.com
- Senhwa Biosciences, Inc.
- No. 225, Peihsin Road
- 10th Floor
- New Taipei City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6492||GTSM (Taipei Exchange)||Yes||Common Shares||TW||TWD||Dec 2014|
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company, identifies and develops therapies for the treatment of cancer. The company is developing CX-4945 that is in phase I/II clinical trial i...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/26 17:28|
|End of Day Share Price||2021/01/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.